|
1.
|
Moghimi SM and Rajabi-Siahboomi AR: Recent
advances in cellular, subcellular and molecular targeting. Adv Drug
Deliv Rev. 41:129–133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Hood JD, Bednarski M, Frausto R, Guccione
S, Reisfeld RA, Xiang R and Cheresh DA: Tumor regression by
targeted gene delivery to the neovasculature. Science.
296:2404–2407. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Hollopeter G, Jantzen HM, Vincent D, Li G,
England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D
and Conley PB: Identification of the platelet ADP receptor targeted
by antithrombotic drugs. Nature. 409:202–207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Low RN, Saleh F, Song SYT, Shiftan TA,
Barone RM, Lacey CG and Goldfarb PM: Treated ovarian cancer:
comparison of MR imaging with serum CA-125 level and physical
examination – a longitudinal study. Radiology. 211:519–528.
1999.PubMed/NCBI
|
|
5.
|
Ke CY, Mathias CJ and Green MA: The folate
receptor as a molecular target for tumor-selective radionuclide
delivery. Nucl Med Biol. 30:811–817. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Brasch RC: Rationale and applications for
macromolecular Gd-based contrast agents. Magn Reson Med.
22:282–287. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Unger EC, Totty WG, Neufeld DM, Otsuka FL,
Murphy WA, Welch MS, Connett JM and Philpott GW: Magnetic resonance
imaging using gadolinium labeled monoclonal antibody. Invest
Radiol. 20:693–700. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Gohr-Rosenthal S, Schmit-Willich H, Ebert
W and Conrad J: The demonstration of human tumors on nude mice
using gadolinium-labeled monoclonal antibodies for magnetic
resonance imaging. Invest Radiol. 28:789–795. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Zuckier LS, Rodriguez LB and Scharff MD:
Immunologic and pharmacologic concepts of monoclonal antibodies.
Semin Nucl Med. 28:166–186. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Leamon CP and Low PS: Delivery of
macromolecules into living cells: a method that exploits folate
receptor endocytosis. Proc Natl Acad Sci USA. 88:5572–5576. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Leamon CP and Low PS: Cytotoxicity of
mormordin-folate conjugates in cultured human cells. J Biol Chem.
267:24966–24971. 1992.PubMed/NCBI
|
|
12.
|
Leamon CP, Pastan I and Low PS:
Cytotoxicity of folate-pseudo-monas exotoxin conjugates toward
tumor cells. Contribution of translocation domain. J Biol Chem.
268:24847–24854. 1993.PubMed/NCBI
|
|
13.
|
Antony AC: Folate receptors. Annu Rev
Nutr. 16:501–521. 1996. View Article : Google Scholar
|
|
14.
|
Garin-Chesa P, Campbell I, Saigo PE, Lewis
JL Jr, Old LJ and Rettig WJ: Trophoblast and ovarian cancer antigen
LK26. Sensitivity and specificity in immunopathology and molecular
identification as a folate-binding protein. Am J Pathol.
142:557–567. 1993.PubMed/NCBI
|
|
15.
|
Ross JF, Chaudhuri PK and Ratnam M:
Differential regulation of folate receptor isoforms in normal and
malignant tissues in vivo and in established cell lines.
Physiologic and clinical implications Cancer. 73:2432–2443.
1994.PubMed/NCBI
|
|
16.
|
Lu Y and Low PS: Folate-mediated delivery
of macromolecular anticancer therapeutic agents. Adv Drug Deliv
Rev. 54:675–693. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Sudimack J and Lee RJ: Targeted drug
delivery via the folate receptor. Adv Drug Deliv Rev. 41:147–162.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Xu L, Pirollo KF and Chang EH:
Tumor-targeted p53-gene therapy enhances the efficacy of
conventional chemo/radiotherapy. J Control Release. 74:115–128.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Maziarz KM, Monaco HL, Shen F and Ratnam
M: Complete mapping of divergent amino acids responsible for
differential ligand binding of folate receptors alpha and beta. J
Biol Chem. 274:11086–11091. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Shen F, Ross JF, Wang X and Ratnam M:
Identification of a novel folate receptor, a truncated receptor,
and receptor type in hematopoietic cells: cDNA cloning, expression,
immunoreactivity, and tissue specificity. Biochem. 33:1209–1215.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Yuan Z, Liu SY, Xiao XS, Zhong GR and
Jiang QJ: Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for
tumor imaging via folate receptor-targeted delivery. Zhonghua Yi
Xue Za Zhi. 87:673–678. 2007.(In Chinese).
|
|
22.
|
Brasch RC: Rationale and applications for
macromolecular Gd-based contrast agents. Magn Reson Med.
22:282–287. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Jain RK: Transport of molecules in the
tumor interstitium: a review. Cancer Res. 47:3039–3051.
1987.PubMed/NCBI
|
|
24.
|
Rijnboutt S, Jansen G, Posthuma G, Hynes
JB, Schornagel JH and Strous GJ: Endocytosis of GPI-linked membrane
folate-receptor-[alpha]. J Cell Biol. 132:35–47. 1996.
|
|
25.
|
Luhrs CA and Slomiany BL: A human
membrane-associated folate binding protein is anchored by a
glycosyl-phospatidylinositol tail. J Biol Chem. 264:21446–21449.
1989.PubMed/NCBI
|
|
26.
|
Kane MA, Elwood PC, Portilla RM, Antony AC
and Kolhouse JF: The interrelationship of the soluble and
membrane-associated folate-binding proteins in human KB cells. J
Biol Chem. 261:15625–15631. 1986.PubMed/NCBI
|
|
27.
|
Antony AC: The biological chemistry of
folate receptors. Blood. 79:2807–2820. 1992.PubMed/NCBI
|
|
28.
|
Wiener EC, Konda S, Shadron A, Brechbiel M
and Gansow O: Targeting dendrimer-chelates to tumors and tumor
cells expressing the high-affinity folate receptor. Invest Radiol.
32:748–754. 1997. View Article : Google Scholar : PubMed/NCBI
|
